Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 5/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | USP2 | O75604 | 2/20 | 0.31 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.31 |
| ▸ | ATP1A1 | P05023 | 1/20 | 0.31 |
| ▸ | ATP1B1 | P05026 | 1/20 | 0.31 |
| ▸ | ATP1A3 | P13637 | 1/20 | 0.31 |
| ▸ | ATP1B2 | P14415 | 1/20 | 0.31 |
| ▸ | ATP1A2 | P50993 | 1/20 | 0.31 |
| ▸ | ATP1B3 | P54709 | 1/20 | 0.31 |
| ▸ | FXYD2 | P54710 | 1/20 | 0.31 |
| ▸ | ATP1A4 | Q13733 | 1/20 | 0.31 |
| ▸ | STAT3 | P40763 | 3/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14819927 | 1.00 | CYP3A4 (0.39) | CYP3A4LMNATP53SMN1; SMN2USP2 | |
| SCHEMBL17145964 | 1.00 | CYP3A4 (0.39) | CYP3A4LMNATP53SMN1; SMN2USP2 | |
| SCHEMBL23277703 | 1.00 | CYP3A4 (0.39) | CYP3A4LMNATP53SMN1; SMN2USP2 | |
| SCHEMBL24106455 | 1.00 | CYP3A4 (0.39) | CYP3A4LMNATP53SMN1; SMN2USP2 | |
| SCHEMBL14819928 | 0.94 | CYP3A4 (0.37) | CYP3A4LMNATP53SMN1; SMN2 | |
| SCHEMBL14805550 | 0.94 | CYP3A4 (0.37) | CYP3A4LMNATP53SMN1; SMN2 | |
| SCHEMBL14819942 | 0.94 | CYP3A4 (0.37) | CYP3A4LMNATP53SMN1; SMN2 | |
| SCHEMBL14819868 | 0.91 | CYP3A4 (0.34) | CYP3A4LMNAUSP2ABCB1ATP1A1 | |
| SCHEMBL13646756 | 0.90 | CYP3A4 (0.36) | CYP3A4LMNATP53SMN1; SMN2ATP1A1 | |
| SCHEMBL7603079 | 0.90 | CYP3A4 (0.36) | CYP3A4LMNATP53SMN1; SMN2ATP1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022034226-A1 | AVERMECTIN AND MILBEMYCIN COMPOSITIONS FOR INHALATION | UNIVERSIDAD DE NAVARRA (ES) | 2022-02-17 | — | — | WO | disclosed |
| US-9662346-B2 | Method of treating hyperesthesia, paresthesia, dolor, and pruritus caused by insect stings or noxious weeds or plants using avermectin compound | GALDERMA S.A. (CH) | 2017-05-30 | — | — | US | disclosed |
| US-9150608-B2 | Neuro-protective compounds and their use | Biotechnology Research Corp. Ltd. (CN) | 2015-10-06 | — | — | US | disclosed |
| US-20150045315-A1 | METHOD OF TREATING HYPERESTHESIA, PARESTHESIA, DOLOR, AND PRURITUS CAUSED BY INSECT STINGS OR NOXIOUS WEEDS OR PLANTS USING AVERMECTIN COMPOUND | GALDERMA S. A. (CH) | 2015-02-12 | — | — | US | disclosed |
| US-8912151-B2 | Method of treating hemorrhoids using macrocyclic lactone compound | GALDERMA S.A. (CH) | 2014-12-16 | — | — | US | disclosed |
| US-8901163-B2 | Method of treating hyperesthesia, paresthesia, dolor, and pruritus caused by insect stings or noxious weeds or plants using avermectin compound | GALDERMA S.A. (CH) | 2014-12-02 | — | — | US | disclosed |
| US-8901163-B2 | Method of treating hyperesthesia, paresthesia, dolor, and pruritus caused by insect stings or noxious weeds or plants using avermectin compound | GALDERMA S.A. (CH) | 2014-12-02 | — | — | US | disclosed |
| US-8541022-B2 | Method of treating burns using avermectin compound | GALDERMA S.A. (CH) | 2013-09-24 | — | — | US | disclosed |
| US-8541022-B2 | Method of treating burns using avermectin compound | GALDERMA S.A. (CH) | 2013-09-24 | — | — | US | disclosed |
| US-20130178433-A1 | METHOD OF TREATING HEMORRHOIDS USING MACROCYCLIC LACTONE COMPOUND | GALDERMA S.A. (CH) | 2013-07-11 | — | — | US | disclosed |
| US-20130079293-A1 | NEURO-PROTECTIVE EFFECTS OF ADELOSTEMMA GRACILLIMUM AND ITS ISOLATED COMPOUNDS | BIOTECHNOLOGY RESEARCH CORPORATION LIMITED (CN) | 2013-03-28 | — | — | US | disclosed |
| US-7897559-B2 | Acne; dermatitis | PARKS L DEAN | 2011-03-01 | — | — | US | disclosed |
| US-20090297589-A1 | Method of treating burns using Avermectin compound | GALDERMA S.A. (CH) | 2009-12-03 | — | — | US | disclosed |
| US-20090297589-A1 | Method of treating burns using Avermectin compound | GALDERMA S.A. (CH) | 2009-12-03 | — | — | US | disclosed |
| US-20080161384-A1 | Topical skin application; immediate relief | GALDERMA S.A. (CH) | 2008-07-03 | — | — | US | disclosed |
| US-20080161384-A1 | Topical skin application; immediate relief | GALDERMA S.A. (CH) | 2008-07-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090297589-A1 | Method of treating burns using Avermectin compound | MMP1, CUTA, HMGB3 | CYP3A4 1449/4885LMNA 388/4885TP53 3898/4885 |
| US-20130079293-A1 | NEURO-PROTECTIVE EFFECTS OF ADELOSTEMMA GRACILLIMUM AND ITS ISOLATED COMPOUNDS | GRIN2B, GRM7, GRM2 | CYP3A4 4471/4885LMNA 4301/4885TP53 4813/4885 |
| US-20130178433-A1 | METHOD OF TREATING HEMORRHOIDS USING MACROCYCLIC LACTONE COMPOUND | VIP, SI, MLEC | CYP3A4 1678/4885LMNA 242/4885TP53 4714/4885 |
| US-20080161384-A1 | Topical skin application; immediate relief | TRPV1, CUTA, TRPV2 | CYP3A4 1784/4885LMNA 2076/4885TP53 4728/4885 |
| US-20150045315-A1 | METHOD OF TREATING HYPERESTHESIA, PARESTHESIA, DOLOR, AND PRURITUS CAUSED BY INSECT STINGS OR NOXIOUS WEEDS OR PLANTS USING AVERMECTIN COMPOUND | TRPV1, CUTA, ITCH | CYP3A4 635/4885LMNA 1711/4885TP53 3361/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.